Tag: Survival

Addition of neoadjuvant and adjuvant pembrolizumab to standard care significantly improves event-free survival

In study, patients with CRC as the only malignancy had more frequent liver and lung metastases and received systemic adjuvant treatments more often

However, poor social determinants of health group demonstrated better survival rates at both 90 days and one year

Medicare beneficiaries undergoing concomitant surgical ablation have risk-adjusted median survival advantage

Longer mean duration of quality-adjusted time without symptoms of disease progression or toxicity of treatment seen with dostarlimab

No reduction seen in risk with adjuvant regional nodal irradiation among patients with node-positive breast cancer who reached ypN0 status after neoadjuvant chemo

Improved survival seen with structured program in patients with resected colon cancer who have completed adjuvant chemo

Progression-free survival longer with vepdegestrant than fulvestrant in subgroup with ESR1 mutations, but not in the overall population

Clinically relevant but not statistically significant improvement seen in anxiety and fatigue versus usual services

Racial differences in treatment common, including lower likelihood of surgery for stage I to II lung cancer in Black patients